Hocini H, Becquart P, Bouhlal H, Adle-Biassette H, Kazatchkine M D, Bélec L
Unité INSERM U430, Paris, France.
Clin Diagn Lab Immunol. 2000 May;7(3):515-8. doi: 10.1128/CDLI.7.3.515-518.2000.
In the present study, we demonstrate that recombinant human secretory leukocyte protease inhibitor (rhSLPI) inhibits infection of lymphocyte- and monocyte-derived tumor cell lines and peripheral blood lymphocytes with laboratory-adapted isolates and with the primary isolate, NDK, of free human immunodeficiency virus type 1 (HIV-1). In contrast, rhSLPI did not exhibit inhibitory activity toward transcytosis of cell-associated HIV-1 through a tight monolayer of endometrial epithelial cells. These observations indicate that the inhibitory effect of SLPI is restricted to free HIV-1 in corporal fluids.
在本研究中,我们证明重组人分泌型白细胞蛋白酶抑制剂(rhSLPI)可抑制实验室适应性分离株以及游离的1型人类免疫缺陷病毒(HIV-1)的原始分离株NDK对淋巴细胞和单核细胞衍生的肿瘤细胞系及外周血淋巴细胞的感染。相比之下,rhSLPI对细胞相关的HIV-1通过紧密的子宫内膜上皮细胞单层进行的转胞吞作用未表现出抑制活性。这些观察结果表明,SLPI的抑制作用仅限于体液中的游离HIV-1。